Hyperuricaemia in cardiovascular diseases: A passive or an active player?

Medical Principles and Practice

Volumn 24, Issue 3, 2015, Pages 269-270

  Katsiki, Niki ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMLODIPINE; ATORVASTATIN; CAPTOPRIL; ENALAPRIL; EZETIMIBE; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; METFORMIN; PIOGLITAZONE; RAMIPRIL; SIMVASTATIN; URIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DYSLIPIDEMIA; HAZARD RATIO; HUMAN; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; METABOLIC SYNDROME X; MORBIDITY; NONALCOHOLIC FATTY LIVER; OBESITY; REGRESSION ANALYSIS; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; THROMBOEMBOLISM; URIC ACID BLOOD LEVEL; ATRIAL FIBRILLATION; BLOOD; FEMALE; HEART ATRIUM APPENDAGE; MALE; PATHOPHYSIOLOGY;

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; URIC ACID;

EID: 84929957143     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000381398     Document Type: Article

References (10)

1. Celik M, Yalcinkaya E, Yuksel UC, Gokoglan Y, Bugan B, Kabul HK, Barcin C: Increased serum uric acid levels are correlated with decreased left atrial appendage peak flow velocity in patients with atrial fibrillation. Med Princ Pract DOI:10.1159/000373892.
2. Numa S, Hirai T, Nakagawa K, et al: Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically low-intermediate risk. Circ J 2014; 78: 1600-1605.
3. Tamariz L, Hernandez F, Bush A, et al: Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 2014; 11: 1102-1108.
4. Chao TF, Liu CJ, Chen SJ, et al: Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation-could it refine clinical risk stratification in AF Int J Cardiol 2014; 170: 344-349.
5. Katsiki N, Karagiannis A, Athyros VG, et al: Hyperuricaemia: more than just a cause of gout J Cardiovasc Med (Hagerstown) 2013; 14: 397-402.
6. Katsiki N, Athyros VG, Karagiannis A, et al: Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk Curr Vasc Pharmacol 2011; 9: 698-705.
7. Katsiki N, Papanas N, Fonseca VA, et al: Uric acid and diabetes: is there a link Curr Pharm Des 2013; 19: 4930-4937.
8. Agabiti-Rosei E, Grassi G: Beyond gout: uric acid and cardiovascular diseases. Curr Med Res Opin 2013; 29(suppl 3):33-39.
9. Høieggen A, Alderman MH, Kjeldsen SE, et al; LIFE Study Group: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
10. Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-599.